TARDBP and dementia: In this study, LBD models including α-synA53T, α-synA53T;Aβ1-42, α-synA53T;TDP-43, α-synA53T;Taupro-agg, and α-synA53T;Aβ1-42;Taupro-agg exhibited phenotypes that corresponded to the clinical symptoms of LBD, such as significant stiffness and inflexibility in the body (Fig. 1), decreases in movement capacity (Fig. 3A), reductions in animal activity (Figs. 3B and 4D), lower body control ability (Fig. 4A–C), dopaminergic neuron deficits (Fig. 4F), α-syn prone to protein aggregation (Fig. 5D), and dementia (Fig. 3E).